Quince Therapeutics (Nasdaq:QNCX) - Aandelenkoers, Nieuws & Analyse

QNCX Overzicht aandelen

Quince Therapeutics, Inc. is een biofarmaceutisch bedrijf dat zich richt op het verwerven, ontwikkelen en commercialiseren van therapeutica voor patiënten met slopende en zeldzame ziekten. Meer informatie

QNCX fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Heeft geen betekenisvolle marktkapitalisatie ( $92M )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

+ 1 meer risico

Quince Therapeutics, Inc. Concurrenten

PDS Biotechnology

NasdaqCM:PDSB

US$81.0m

PMV Pharmaceuticals

NasdaqGS:PMVP

US$83.3m

MDxHealth

NasdaqCM:MDXH

US$80.9m

BioAtla

NasdaqGM:BCAB

US$67.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Quince Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$1.96
52 Week Hoogtepunt	US$2.45
52 Week Laag	US$0.51
Bèta	0.71
11 maand verandering	125.29%
3 maanden verandering	196.97%
1 Jaar Verandering	106.25%
33 jaar verandering	-83.71%
5 jaar verandering	-92.53%
Verandering sinds IPO	-94.04%

Recent nieuws en updates

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Aug 20

Recent updates

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Aug 20

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Nov 21

Insider Buying: The Cortexyme, Inc. (NASDAQ:CRTX) Independent Director Just Bought 2.4% More Shares

Mar 10

Rendement voor aandeelhouders

	QNCX	US Biotechs	US Markt
7D	10.1%	-3.7%	0.3%
1Y	106.3%	15.2%	31.1%

Rendement versus industrie: QNCX overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 15.2 % opleverde.

Rendement versus markt: QNCX overtrof de US markt, die het afgelopen jaar een rendement opleverde van 31.1 %.

Prijsvolatiliteit

Is QNCX's price volatile compared to industry and market?
QNCX volatility
QNCX Average Weekly Movement	17.9%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van QNCX is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van QNCX is het afgelopen jaar gestegen van 12% naar 18%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2012	32	Dirk Thye	www.quincetx.com

Quince Therapeutics, Inc, een biofarmaceutisch bedrijf, richt zich op het verwerven, ontwikkelen en commercialiseren van therapeutica voor patiënten met slopende en zeldzame ziekten. De belangrijkste kandidaat van het bedrijf is EryDex voor de behandeling van zeldzame pediatrische neurodegeneratieve ziekten, waaronder A-T, een erfelijke autosomaal recessieve neurodegeneratieve en immunodeficiëntie stoornis veroorzaakt door mutaties in het ATM-gen. Het AIDE-technologieplatform, een combinatieplatform van medicijnen en hulpmiddelen dat gebruikmaakt van een geautomatiseerd proces om een medicijn in te kapselen in de eigen rode bloedcellen van de patiënt, bestaat uit geautomatiseerde apparatuur, de RCL, een steriele, eenmalig te gebruiken behandelkit bestaande uit EryKit, Spuitkit, medicijnen en procesoplossingen.

Quince Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Quince Therapeutics zich tot de beurswaarde?
QNCX fundamentele statistieken
Marktkapitalisatie	US$91.52m
Inkomsten(TTM)	-US$53.26m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-1.6x

Koers/Winstverhouding

Is QNCX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
QNCX resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$53.26m
Inkomsten	-US$53.26m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.21
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	33.2%

Hoe presteerde QNCX op de lange termijn?

Bekijk historische prestaties en vergelijking

QNCX Overzicht aandelen

Risicoanalyse

Quince Therapeutics, Inc. Concurrenten

NasdaqCM:PDSB

US$81.0m

NasdaqGS:PMVP

US$83.3m

NasdaqCM:MDXH

US$80.9m

NasdaqGM:BCAB

US$67.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New minor risk - Shareholder dilution

Quince Therapeutics Presents Safety Data from Prior Phase 3 Attest Clinical Trial At 53rd Child Neurology Society Annual Meeting

New minor risk - Profitability

CEO, Chief Medical Officer & Director recently bought US$107k worth of stock

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Quince Therapeutics, Inc. Announces the Online Publication of Data in the Lancet Neurology from Its Phase 3 Attest Clinical Trial Data Evaluating Erydex for the Treatment of Ataxia-Telangiectasia (A-T)

Recent updates

New minor risk - Shareholder dilution

Quince Therapeutics Presents Safety Data from Prior Phase 3 Attest Clinical Trial At 53rd Child Neurology Society Annual Meeting

New minor risk - Profitability

CEO, Chief Medical Officer & Director recently bought US$107k worth of stock

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Quince Therapeutics, Inc. Announces the Online Publication of Data in the Lancet Neurology from Its Phase 3 Attest Clinical Trial Data Evaluating Erydex for the Treatment of Ataxia-Telangiectasia (A-T)

Quince Therapeutics, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024

Quince Therapeutics Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Quince Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EryDex System

Quince Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Quince Therapeutics, Inc. Launches Scientific Advisory Board

Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors

CEO & Director exercised options to buy US$336k worth of stock.

Independent Chairman of the board recently bought US$58k worth of stock

Quince Therapeutics Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer

Insufficient new directors

New minor risk - Shareholder dilution

Quince Therapeutics, Inc. Appoints Luca Benatti as Director

Quince Therapeutics, Inc. (NasdaqGS:QNCX) acquired EryDel S.p.A. for approximately $510 million.

Quince Therapeutics, Inc. Announces That U.S. Food and Drug Administration Lifts the Partial Clinical Hold on Erydel S.P. A's Investigational New Drug (Ind) Application for Its Lead Phase 3 Asset, Erydex

Quince Therapeutics Appoints Charles S. Ryan as President

Independent Chairman of the board recently bought US$108k worth of stock

Quince Therapeutics, Inc. Announces the Departure of Karen Smith as Chief Medical Officer, Effective September 1, 2023

CEO, President & Director recently bought US$99k worth of stock

New minor risk - Share price stability

Quince Therapeutics, Inc. (NasdaqGS:QNCX) agreed to acquire EryDel S.p.A. for approximately $490 million.

Biomed Industries, Inc. submitted a proposal to acquire Quince Therapeutics, Inc. (NasdaqGS:QNCX) for $10.5 million.

Price target increased by 56% to US$12.00

Quince Therapeutics Gets an Initial Compliance Period of 180 Calendar Days to Regain Compliance with the Minimum Bid Price Requirement

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Insufficient new directors

Insufficient new directors

Quince Therapeutics, Inc. Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures

Price target increased to US$8.38

Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

Cortexyme to change name and ticker symbol next month

Cortexyme, Inc. Announces Resignation of Leslie Holsinger as Executive Vice President of Research and Development, Effective July 31, 2022

Cortexyme, Inc.(NasdaqGS:CRTX) dropped from Russell 2000 Dynamic Index

Cortexyme, Inc. Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

Cortexyme, Inc. Appoints June Bray to its Board of Directors

Cortexyme, Inc. Announces Resignation of Christopher Lowe as Chief Financial Officer

Cortexyme, Inc. (NasdaqGS:CRTX) acquired Novosteo Inc. from David Lamond and others for $19.8 million.

Dr. Dirk Thye and Philip Low to Join Cortexyme Board

Price target decreased to US$7.60

Cortexyme, Inc. Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of Its Phase 1 Clinical Trial of Cor588

Price target decreased to US$7.60

Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment

Cortexyme, Inc. Announces Executives Changes

Cortexyme, Inc. Receives Letter from the U.S. Food and Drug Administration, Placing Full Clinical Hold on Atuzaginstat’s (COR388) Investigational New Drug Application

Price target increased to US$44.00

Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors

We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate

COO, CFO & Treasurer exercised options to buy US$387k worth of stock.

Cortexyme: A Challenging Path Forward

Cortexyme: Positive Lessons To Be Learned From Disappointing Results

Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease

COO, CFO & Treasurer exercised options and sold US$217k worth of stock

Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021

Cortexyme: Alzheimer's Readout In November A Binary Event